Lamotrigine and Levetiracetam Serum/Plasma Levels and Toxicity

Published: 28 October 2021| Version 1 | DOI: 10.17632/fxbmcb8czp.1
Contributors:
Matthew Krasowski,
,

Description

Supplementary file 1: Data for 5,046 measurements of lamotrigine serum/plasma drug levels on 1,930 unique patients (1,068 female, 862 male). The retrospective timeframe is August 1, 1996 through November 15, 2018. Supplementary file 2: Data for 597 measurements on 293 unique patients (163 female, 130 male) for which the lamotrigine serum/plasma drug level was greater than 14.0 mg/L. Data includes information from detailed chart review. The retrospective timeframe is August 1, 1996 through November 15, 2018. Supplementary file 3: Data for 4,359 measurements of levetiracetam serum/plasma drug levels on 2,451 unique patients (1,225 female, 1,226 male). The retrospective timeframe is January 1, 2005 and November 15, 2018. Supplementary file 4: Data for 134 measurements on 106 unique patients (33 female, 73 male) for which the levetiracetam serum/plasma drug level was 80 mg/L or higher. Data includes information from detailed chart review. The retrospective timeframe is January 1, 2005 and November 15, 2018.

Files

Steps to reproduce

Retrospective data was obtained from the electronic medical record (Epic, Inc.) covering the time period between August 1, 1996 through November 15, 2018 for lamotrigine and between January 1, 2005 and November 15, 2018 for levetiracetam. A reporting tool within the electronic medical record, known as Epic Reporting Workbench, was used to identify all tests performed in the retrospective timeframe. Detailed chart review was performed if lamotrigine drug level was greater than 14.0 mg/L or levetiracetam drug level was 80 mg/L or higher. The study had approval as a retrospective study from the University of Iowa Institutional Review Board. Reference: Wood KE, Palmer KL, Krasowski MD. Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center. Toxicol Rep. 2021 Aug 30;8:1592-1598. doi: 10.1016/j.toxrep.2021.08.005. PMID: 34522622

Institutions

University of Iowa

Categories

Pharmacokinetics, Neurotoxicity, Cardiotoxicity, Therapeutic Drug Monitoring

License